Newsmeme!
Discover News you didn't know existed
Pharmacokinetic
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
PharmaEngine wins approval for Phase II pancreatic cancer study
Published December 5, 2008, 2:49 am, Pharmaceutical Business Review
PharmaEngine, a biopharmaceutical company, has received approval of an investigational new drug application from the FDA for PEP02, a liposome formulation of irinotecan in a Phase II study in patients with metastatic pancreatic cancer.
TorreyPines' NGX426 meets endpoints in reducing spontaneous pain
Published December 5, 2008, 1:51 am, PharmaBiz
TorreyPines Therapeutics, Inc announced that oral administration of NGX426, an AMPA/kainate-type glutamate receptor antagonist, demonstrated a statistically significant reduction in spontaneous pain, hyperalgesia (abnormally increased pain state) and allodynia (pain resulting from normally non-painful stimuli to the skin) compared to placebo following intradermal injections of capsaicin in a ...
ConjuChem's PC-DAC(TM):Exendin-4 Lowers Glucose And Weight In Phase II Diabetes Trials
Published December 4, 2008, 7:13 am, Medical News Today
ConjuChem Biotechnologies, Inc. (TSX:CJB) announced preliminary results today showing that its Type 2 diabetes product, PC-DAC(TM):Exendin-4, achieved statistically significant reductions in HbA1c and weight in its two Phase II clinical trials.
Alkermes Initiates Clinical Trial for ALKS 33, a Novel Oral Molecule with Potential Benefits in Addiction and Other ...
Published December 4, 2008, 5:47 am, Centre Daily Times
Alkermes, Inc. (NASDAQ: ALKS) today announced the initiation of a phase 1 study of ALKS 33, an oral opioid modulator for the potential treatment of addiction and other central nervous system (CNS) disorders. ALKS 33 is the company’s first novel, small molecule drug candidate to enter the clinic. The molecule builds on Alkermes’ scientific expertise in brain reward pathways as well as the ...
Alkermes Initiates Clinical Trial for ALKS 33, a Novel Oral Molecule with Potential Benefits in Addiction and Other ...
Published December 4, 2008, 5:30 am, Business Wire via Yahoo! Finance
CAMBRIDGE, Mass.----Alkermes, Inc. today announced the initiation of a phase 1 study of ALKS 33, an oral opioid modulator for the potential treatment of addiction and other central nervous system disorders.
Data on Stapled Peptide Drugs to Be Presented at ASH Annual Meeting
Published December 4, 2008, 5:00 am, Business Wire via Yahoo! Finance
CAMBRIDGE, Mass.----Aileron Therapeutics announced today that investigators from Aileron and the Dana-Farber Cancer Institute will present data from multiple preclinical studies on stapled peptide drug candidates at the 50th Annual Meeting of the American Society of Hematology in San Francisco, Calif., December 6 to 9, 2008.
ConjuChem's PC-DAC(TM):Exendin-4 Lowers Glucose and Weight in Phase II Diabetes Trials
Published December 3, 2008, 2:52 pm, PR Newswire via Yahoo! Finance
ConjuChem Biotechnologies, Inc. announced preliminary results
ConjuChem's PC-DAC(TM):Exendin-4 Lowers Glucose and Weight in Phase II Diabetes Trials
Published December 3, 2008, 1:23 pm, PR Newswire via Yahoo! Finance
Product Extremely Well Tolerated -
PharmaEngine Receives Approval Of US IND Application For A Phase II Study Of PEP02 (Liposome Irinotecan Injection) In ...
Published December 3, 2008, 12:11 pm, Medical News Today
PharmaEngine, Inc. announced today that it has received approval of an Investigational New Drug (IND) application from the U.S. FDA for PEP02, a liposome formulation of irinotecan in a phase II study in patients with metastatic pancreatic cancer.
Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S., Named New Director of the National Institute of Environmental Health ...
Published December 3, 2008, 9:55 am, National Institutes of Health
Dr. Raynard S. Kington, acting director of the National Institutes of Health (NIH), today announced the appointment of Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S., as director of the National Institute of Environmental Health Sciences (NIEHS). Dr. Birnbaum, who is currently a senior advisor at the Environmental Protection Agency (EPA), where she served for 16 years as director of the Experimental ...
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |